Xidea Solutions Ltd   Report issue

For profit Phase 3
Founded: Surrey United Kingdom (2006)

Organization Overview

First Clinical Trial
2009
NCT01047436
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2015

Timeline

NOW
  • Now

Alternative names

Xidea Solutions Limited | Xidea Solutions Ltd.

Active Ingredients

Drugs in Phase 3 Trials (2)

coartem (4 trials)

quinine (qualaquin) (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Malaria (Phase 3)

Malaria, Falciparum (Phase 3)

Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 4
  • # of Trial APIs: 2